Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00713648
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Newcastle upon Tyne, United Kingdom
Observational Study Describing Conditions for Intensification of Insulin Therapy in Type 2 Diabetes
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 114
- Registration Number
- NCT00712478
Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX
- First Posted Date
- 2008-07-04
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT00710619
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 216
- Registration Number
- NCT00709683
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2171
- Registration Number
- NCT00709917
Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 747
- Registration Number
- NCT00709475
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study to Evaluate the Safety of Levemir® in Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2282
- Registration Number
- NCT00706017
- Locations
- 🇲🇽
Novo Nordisk Investigational Site, Mexico City, Mexico
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 159
- Registration Number
- NCT00704574
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Lund, Sweden
Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 41
- Registration Number
- NCT00705172
Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00703911
- Locations
- 🇻🇪
Novo Nordisk Investigational Site, Caracas, Venezuela
© Copyright 2024. All Rights Reserved by MedPath